{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:19Z","timestamp":1792788079092,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270198"],"award-info":[{"award-number":["82270198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470237"],"award-info":[{"award-number":["82470237"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-0022"],"award-info":[{"award-number":["CIRP-SYSUCC-0022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01697-z","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T09:51:30Z","timestamp":1745747490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and\/or refractory peripheral T-cell lymphoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Huangming","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zegeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"Shuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fugen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"issue":"1","key":"1697_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-024-01560-7","volume":"17","author":"EWY Chang","year":"2024","unstructured":"Chang EWY, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024;17(1):38.","journal-title":"J Hematol Oncol"},{"key":"1697_CR2","doi-asserted-by":"crossref","unstructured":"Shea L, Mehta-Shah N. Peripheral T-cell lymphoma: are all patients high risk? Blood. 2024 Dec 19;144(25):2604\u201312.","DOI":"10.1182\/blood.2023020912"},{"issue":"7","key":"1697_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"10","key":"1697_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood. 2014;124(10):1570\u20137.","journal-title":"Blood"},{"issue":"1","key":"1697_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-023-01904-w","volume":"23","author":"Y Luan","year":"2024","unstructured":"Luan Y, Li X, Luan Y, et al. Therapeutic challenges in peripheral T-cell lymphoma. Mol Cancer. 2024;23(1):2.","journal-title":"Mol Cancer"},{"issue":"7","key":"1697_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project. Haematologica. 2018;103(7):1191\u20137.","journal-title":"Haematologica"},{"issue":"16","key":"1697_CR7","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970\u20136.","journal-title":"J Clin Oncol"},{"key":"1697_CR8","doi-asserted-by":"crossref","unstructured":"Bennani NN, Kim HJ, Pederson LD et al. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022;10(6).","DOI":"10.1136\/jitc-2022-004984"},{"issue":"1","key":"1697_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu J, Wang Z, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021;14(1):12.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1697_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1697_CR11","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","volume":"2","author":"D Tan","year":"2015","unstructured":"Tan D, Phipps C, Hwang WY, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015;2(8):e326\u2013333.","journal-title":"Lancet Haematol"},{"key":"1697_CR12","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Stuver RN, Horwitz SM. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs). Blood. 2024 Oct 31;144(18):1887\u201397.","DOI":"10.1182\/blood.2023021789"},{"issue":"24","key":"1697_CR13","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","volume":"80","author":"ML Eich","year":"2020","unstructured":"Eich ML, Athar M, Ferguson JE 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80(24):5449\u201358.","journal-title":"Cancer Res"},{"issue":"9","key":"1697_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41556-021-00744-4","volume":"23","author":"L Xin","year":"2021","unstructured":"Xin L. EZH2 accompanies prostate cancer progression. Nat Cell Biol. 2021;23(9):934\u20136.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"1697_CR15","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","volume":"29","author":"M Yamagishi","year":"2019","unstructured":"Yamagishi M, Hori M, Fujikawa D, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321\u2013e23372327.","journal-title":"Cell Rep"},{"issue":"1","key":"1697_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1697_CR17","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","volume":"9","author":"Y Song","year":"2022","unstructured":"Song Y, Liu Y, Li ZM, et al. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol. 2022;9(7):e493\u2013503.","journal-title":"Lancet Haematol"},{"issue":"11","key":"1697_CR18","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"issue":"16","key":"1697_CR19","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b00855","volume":"59","author":"X Yang","year":"2016","unstructured":"Yang X, Li F, Konze KD, et al. Structure-activity relationship studies for enhancer of Zeste homologue 2 (EZH2) and enhancer of Zeste homologue 1 (EZH1) inhibitors. J Med Chem. 2016;59(16):7617\u201333.","journal-title":"J Med Chem"},{"issue":"16","key":"1697_CR20","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","volume":"23","author":"O Rizq","year":"2017","unstructured":"Rizq O, Mimura N, Oshima M, et al. Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition. Clin Cancer Res. 2017;23(16):4817\u201330.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1697_CR21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023;141(10):1159\u201368.","journal-title":"Blood"},{"key":"1697_CR22","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Izutsu K, Mehta-Shah N, et al. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2024 Dec;25(12):1602\u201313.","DOI":"10.1016\/S1470-2045(24)00503-5"},{"issue":"12Supplement","key":"1697_CR23","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1158\/1538-7445.AM2022-5436","volume":"82","author":"X-X Chen","year":"2022","unstructured":"Chen X-X, Shen Q-Q, Zhao Z, et al. Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1\/2 with potent anti-tumor activities. Cancer Res. 2022;82(12Supplement):5436\u20135436.","journal-title":"Cancer Res"},{"issue":"16suppl","key":"1697_CR24","doi-asserted-by":"publisher","first-page":"11562","DOI":"10.1200\/JCO.2023.41.16_suppl.11562","volume":"41","author":"Z Fan","year":"2023","unstructured":"Fan Z, Wang J, Fang M, et al. HH2853, an EZH1\/2 inhibitor, in patients with epithelioid sarcoma: preliminary results from the phase 1 part of a first-in-human phase I\/II study. J Clin Oncol. 2023;41(16suppl):11562\u201311562.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1697_CR25","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1697_CR26","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169\u201378.","journal-title":"Ann Oncol"},{"issue":"26","key":"1697_CR27","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337.","journal-title":"Blood"},{"issue":"6","key":"1697_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1697_CR29","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1697_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108(3):811\u201321.","journal-title":"Haematologica"},{"issue":"16","key":"1697_CR31","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.02367","volume":"41","author":"H Huang","year":"2023","unstructured":"Huang H, Tao R, Hao S, et al. Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study. J Clin Oncol. 2023;41(16):3032\u201341.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1697_CR32","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","volume":"34","author":"JQ Lim","year":"2020","unstructured":"Lim JQ, Huang D, Tang T, et al. Whole-genome sequencing identifies responders to pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma. Leukemia. 2020;34(12):3413\u20139.","journal-title":"Leukemia"},{"key":"1697_CR33","doi-asserted-by":"publisher","first-page":"869488","DOI":"10.3389\/fphar.2022.869488","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Wu W, Wei W, Zou L. Immune checkpoint inhibitors in peripheral T-cell lymphoma. Front Pharmacol. 2022;13:869488.","journal-title":"Front Pharmacol"},{"issue":"23","key":"1697_CR34","doi-asserted-by":"publisher","first-page":"e2308045","DOI":"10.1002\/advs.202308045","volume":"11","author":"J Huang","year":"2024","unstructured":"Huang J, Yin Q, Wang Y, et al. EZH2 inhibition enhances PD-L1 protein stability through USP22-mediated deubiquitination in colorectal cancer. Adv Sci (Weinh). 2024;11(23):e2308045.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"1697_CR35","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-23-2582","volume":"30","author":"Y Song","year":"2024","unstructured":"Song Y, Jin Z, Li ZM, et al. Enhancer of Zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study. Clin Cancer Res. 2024;30(7):1248\u201355.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01697-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01697-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01697-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T09:51:32Z","timestamp":1745747492000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01697-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01697-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols received approval from the ethics committees at each participation center. All patients provided written informed consent, and the study adhered to the principles outlined in the Declaration of Helsinki. This study has been registered with ClinicalTrials.gov under the identifier NCT04390737.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"NCT04390737","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial information"}}],"article-number":"50"}}